Genprex

© 2023 © 2020 Genprex Inc. All Rights Reserved.

Investor

Downloads

Investor Presentation

Review our latest corporate presentation with an overview of company highlights, recent milestones and clinical updates.

Download

2023 AACR Abstract – NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human NSCLC in a humanized mouse model

The abstract reports NPRL2 gene therapy induces effective anti-tumor activity in non-small cell lung cancer pembrolizumab resistant tumors in a humanized mouse model and provides preclinical validation of the ONCOPREX® Nanoparticle Delivery System with a second tumor suppressor gene

Download

ATTD 2023 – Pancreatic Intraductal Infusion of Adeno-Associated Virus To Treat Non- Human Primates in a Toxin-Induced Diabetes Model

Data highlighting the potential of Genprex’s gene therapy for Type 1 diabetes was being presented by its research collaborators at the University of Pittsburgh at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) on February 25, 2023 in Berlin, Germany.

Download

Fact Sheet

A one-page fact sheet and overview of Genprex.

Download

TUSC2 Bibliography

A bibliography of selected publications describing the TUSC2 gene.

Download

PDX1 and MAFA Bibliography

A bibliography of selected publications describing the PDX1 and MAFA genes.

Download

2021 AACR Poster – Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC – Meraz

The poster presents positive preclinical data for REQORSA in combination with Tagrisso®, demonstrating synergistic antitumor efficacy in EGFR mutant Tagrisso resistant NSCLC tumors in H1975-OsiR isogenic tumors. Researchers also found that the upregulation of PDK1 was associated with osimertinib resistance.

Download

2020 International Journal of Molecular Sciences

The study found TUSC2 may be a novel target and biomarker for thyroid cancer therapy.

Download

2019 AACR KRAS and LKB1 Poster – Meraz

The poster demonstrates research and data on the efficacy of novel immunogene combinations for KRAS and LKB1 mutant NSCLC in a humanized mouse model.

Download

2019 Nature Research Scientific Reports

The study found that TUSC2 prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options.

Download

2019 AACR Hu-PDX Poster – Meraz

The poster presents positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a humanized mouse model.

Download

2012 AACR Poster – Yan

The poster describes a novel anticancer therapeutic strategy using a new class of rationally designed dual DNA alkylating/HDAC inhibitors combined with nanoparticle-mediated gene therapy targeting the DNA damage/repair pathway in human NSCLC and SCLC cells.

Download

2012 AACR Poster – Meng

The poster presents data on the synergistic antitumor activity of MK2206 and TUSC2/FUS1-nanoparticle in NSCLC.

Download